Plaque PsoriasisADMIRENCT06512337
A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China
An observational study of Plaque Psoriasis, run by Bristol-Myers Squibb at 5 sites in China.
Trial summary
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Plaque Psoriasis
- What is being tested?
- Deucravacitinib
- How many people
- 153 participants
- Where
- 5 sitesChina
- Study dates
- 20 Jan 2025to 11 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult participants aged ≥ 18 years who have been diagnosed with moderate plaque psoriasis who are starting deucravacitinib treatment in China
Who may be able to join
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Who cannot join
- Participating in or planning to participate in an interventional clinical trial
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
China5 sites
Local Institution - 0003
Beijing, 102218
Local Institution - 0005
Dalian, Liaoning, 116021
Local Institution - 0001
Guangzhou, Guangdong, 510091
Local Institution - 0002
Handan, Hebei, 056029
Local Institution - 0004
Shanghai, Shanghai Municipality, 200080
About this study
Official title: A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
- Conditions
- Plaque Psoriasis
- Being tested
- Deucravacitinib
- Keywords
- Plaque psoriasis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DeucravacitinibDrug
As per product label
| Study group | Role | What they receive |
|---|---|---|
| Participants treated with deucravacitinib | Adults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label Receives: Drug: Deucravacitinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score
Measured: Week 16
Participant psoriasis Body Surface Area (BSA) involvement
Measured: Week 16
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3
Measured: Week 16
Secondary outcomes (10)
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response
Measured: Baseline and Weeks 4, 12, 24, 36, and 52
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5
Measured: Baseline and Weeks 4, 12, 24, 36, and 52
Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline
Measured: Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%
Measured: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in Body Surface Area (BSA) involvement from baseline to follow-up
Measured: Weeks 4, 12, 24, 36, and 52
Static Physician's Global Assessment (sPGA) 0/1 response at follow-up
Measured: Weeks 4, 12, 24, 36, and 52
Participants change in Static Physician's Global Assessment (sPGA) score from baseline
Measured: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score
Measured: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score
Measured: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in participant Dermatology Life Quality Index (DLQI) score from baseline
Measured: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2024
- Study start20 Jan 2025
- Primary completion11 Mar 2027 (estimated)
- Study completion11 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Plaque PsoriasisStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 153 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06512337
- Sponsor's protocol ID
- IM011-1180
- Acronym
- ADMIRE
- Status last verified
- Apr 2026
- First submitted
- 16 Jul 2024
- Last updated
- 15 Apr 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Zhang Z, Tan X, Wu Z, Zhou J. Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study. J Dermatolog Treat. 2026 Dec;37(1):2635262. doi: 10.1080/09546634.2026.2635262. Epub 2026 Mar 2.
PubMed 41769731
Study at a glance
From the registry record, last updated by the sponsor on 15 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
- ClinicalTrials.gov ID
- NCT06512337
- Acronym / sponsor ID
- ADMIRE / IM011-1180
- Conditions
- Plaque Psoriasis
- Keywords
- Plaque psoriasis
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 153 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 20 Jan 2025 (actual)
- Primary completion
- 11 Mar 2027 (estimated)
- Study completion
- 11 Mar 2027 (estimated)
- First posted
- 22 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to collect and evaluate real-world data on the effectiveness of deucravacitinib treatment in adults with moderate plaque psoriasis in China.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants treated with deucravacitinib | – | Drug: DeucravacitinibAdults with moderate plaque psoriasis who are newly initiating deucravacitinib according to the product label |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult participants aged ≥ 18 years who have been diagnosed with moderate plaque psoriasis who are starting deucravacitinib treatment in China
Key inclusion criteria (4 listed)
- Participant aged 18 years or older
- Physician-reported (dermatologist) diagnosis of moderate plaque psoriasis with Body Surface Area ≥ 3% and < 10%
- Participant newly initiated deucravacitinib according to the label
- Provided written informed consent to participate in the study
Key exclusion criteria (3 listed)
- Participating in or planning to participate in an interventional clinical trial
- Concomitant use of other systemic treatments for psoriasis at baseline
- Prior treatment of deucravacitinib
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DeucravacitinibAs per product label | Drug | Participants treated with deucravacitinib |
Primary outcome
Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score
Time frame: Week 16
Participant psoriasis Body Surface Area (BSA) involvement
Time frame: Week 16
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤ 3
Time frame: Week 16
10 secondary outcomes
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 response and PASI 90 response
Time frame: Baseline and Weeks 4, 12, 24, 36, and 52
Number of participants achieving absolute Psoriasis Area and Severity Index (PASI) score ≤1, ≤2, ≤3, and ≤5
Time frame: Baseline and Weeks 4, 12, 24, 36, and 52
Participants change in Participant Absolute Psoriasis Area and Severity Index (PASI) score from baseline
Time frame: Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving psoriasis Body Surface Area (BSA) involvement of ≤1% and ≤3%
Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in Body Surface Area (BSA) involvement from baseline to follow-up
Time frame: Weeks 4, 12, 24, 36, and 52
Static Physician's Global Assessment (sPGA) 0/1 response at follow-up
Time frame: Weeks 4, 12, 24, 36, and 52
Participants change in Static Physician's Global Assessment (sPGA) score from baseline
Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) 0/1 score
Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Number of participants achieving a Dermatology Life Quality Index (DLQI) ≤ 3 score
Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Change in participant Dermatology Life Quality Index (DLQI) score from baseline
Time frame: Baseline and Weeks 4, 12, 16, 24, 36, and 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Apr 2026.
- Derived from this study: PubMed 41769731Zhang Z, Tan X, Wu Z, Zhou J. Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study. J Dermatolog Treat. 2026 Dec;37(1):2635262. doi: 10.1080/09546634.2026.2635262. Epub 2026 Mar 2.
- BMS Clinical Trial InformationLink provided by the sponsor.
- FDA Safety Alerts and RecallsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Plaque Psoriasis
Active, not recruitingObservational study
Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease Burden
Psoriasis, Moderate to Severe Psoriasis
RecruitingObservational study
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
Acne, Atopic Dermatitis
RecruitingPhase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
RecruitingPhase 1
A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001)
Psoriasis, Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Plaque Psoriasis, run by Bristol-Myers Squibb at 5 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 15 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score (time frame: Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06512337, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Apr 2026.